VEXAS Syndrome with Vibrio vulnificus Sepsis during Treatment with Tocilizumab.

Eiko Kawakami, Takahisa Suzuki, Sousuke Tsuji, Takeharu Kato, Kuniko Abe, Tomohiro Koga, Atsushi Kawakami

Abstract readCase Reports

In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Eiko KawakamiDepartment of Rheumatology, Japanese Red Cross Nagasaki Genbaku Hospital, Japan.

Takahisa SuzukiDepartment of Rheumatology, Japanese Red Cross Nagasaki Genbaku Hospital, Japan.

Sousuke TsujiDepartment of Rheumatology, Japanese Red Cross Nagasaki Genbaku Hospital, Japan.

Takeharu KatoDepartment of Hematology, Nagasaki University Hospital, Japan.

Kuniko AbeDepartment of Pathology, Japanese Red Cross Nagasaki Genbaku Hospital, Japan.

Tomohiro KogaDepartment of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan.

Atsushi KawakamiDepartment of Rheumatology, Japanese Red Cross Nagasaki Genbaku Hospital, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the first case of Vibrio vulnificus sepsis in a patient with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome. A 76-year-old man was diagnosed with VEXAS and myelodysplastic syndromes. He was treated with tocilizumab, oral prednisolone, and regular blood transfusions. The patient presented with fever, chills, and vomiting and was subsequently diagnosed with sepsis. A blood culture confirmed V. vulnificus infection, which resolved after tazobactam/piperacillin treatment. V. vulnificus infections can be facilitated by iron overload resulting from frequent blood transfusions. Since patients with VEXAS syndrome often require regular transfusions, clinicians should monitor for this potentially fatal infection.

Indexed as

Antibodies, Monoclonal, HumanizedMyelodysplastic SyndromesSepsisVibrio InfectionsVibrio vulnificusAgedAnti-Bacterial AgentsHumansMalePenicillanic AcidPiperacillinSkin Diseases, GeneticAnti-Bacterial AgentsAntibodies, Monoclonal, HumanizedPenicillanic AcidPiperacillintocilizumabmyelodysplastic syndromes (MDS)tocilizumab (TCZ)VEXAS syndromeVibrio vulnificus

Identifiers

PMID41485921

DOI10.2169/internalmedicine.6479-25

PMCPMC13561569

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.